Vericel Co. (NASDAQ:VCEL) Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC raised its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 9.7% in the second quarter, Holdings Channel.com reports. The firm owned 2,484 shares of the biotechnology company’s stock after buying an additional 220 shares during the period. Nisa Investment Advisors LLC’s holdings in Vericel were worth $114,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of Vericel by 7.0% during the second quarter. SG Americas Securities LLC now owns 11,881 shares of the biotechnology company’s stock worth $545,000 after buying an additional 779 shares in the last quarter. OLD National Bancorp IN acquired a new stake in shares of Vericel in the 2nd quarter valued at about $205,000. Juncture Wealth Strategies LLC lifted its position in shares of Vericel by 95.7% during the second quarter. Juncture Wealth Strategies LLC now owns 7,860 shares of the biotechnology company’s stock worth $361,000 after purchasing an additional 3,843 shares during the last quarter. Contravisory Investment Management Inc. acquired a new position in Vericel in the second quarter worth about $208,000. Finally, Linden Thomas Advisory Services LLC increased its holdings in Vericel by 2.6% in the second quarter. Linden Thomas Advisory Services LLC now owns 42,981 shares of the biotechnology company’s stock valued at $1,972,000 after buying an additional 1,105 shares during the last quarter.

Insider Transactions at Vericel

In other news, insider Sean C. Flynn sold 6,772 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $45.02, for a total value of $304,875.44. Following the transaction, the insider now directly owns 487 shares of the company’s stock, valued at $21,924.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Sean C. Flynn sold 1,474 shares of Vericel stock in a transaction on Monday, June 24th. The shares were sold at an average price of $45.84, for a total value of $67,568.16. Following the completion of the sale, the insider now owns 487 shares of the company’s stock, valued at approximately $22,324.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Sean C. Flynn sold 6,772 shares of the company’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $45.02, for a total transaction of $304,875.44. Following the completion of the sale, the insider now owns 487 shares of the company’s stock, valued at $21,924.74. The disclosure for this sale can be found here. Insiders sold 63,791 shares of company stock valued at $3,101,269 over the last three months. 5.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

VCEL has been the topic of a number of research analyst reports. HC Wainwright increased their target price on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Stephens boosted their target price on shares of Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. StockNews.com lowered shares of Vericel from a “hold” rating to a “sell” rating in a report on Friday, August 2nd. Canaccord Genuity Group assumed coverage on shares of Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 price objective on the stock. Finally, Canaccord Genuity Group assumed coverage on Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 target price for the company. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $55.13.

Vericel Price Performance

Shares of VCEL opened at $49.29 on Monday. The company has a 50-day moving average of $47.47 and a two-hundred day moving average of $47.37. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -4,929.00 and a beta of 1.70. Vericel Co. has a one year low of $30.18 and a one year high of $54.08.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $52.70 million for the quarter, compared to analysts’ expectations of $52.59 million. Vericel had a net margin of 0.37% and a return on equity of 0.35%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.11) EPS. Analysts anticipate that Vericel Co. will post 0.11 earnings per share for the current year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.